Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $88.6 million.

  • Sangamo Therapeutics' Liabilities and Shareholders Equity fell 2033.02% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $374.0 million, marking a year-over-year decrease of 2498.33%. This contributed to the annual value of $101.6 million for FY2024, which is 3852.23% down from last year.
  • According to the latest figures from Q3 2025, Sangamo Therapeutics' Liabilities and Shareholders Equity is $88.6 million, which was down 2033.02% from $97.6 million recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Liabilities and Shareholders Equity peaked at $877.1 million during Q1 2021, and registered a low of $86.2 million during Q1 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $325.1 million (2023), whereas its average is $394.3 million.
  • As far as peak fluctuations go, Sangamo Therapeutics' Liabilities and Shareholders Equity surged by 5011.66% in 2021, and later plummeted by 7138.68% in 2024.
  • Sangamo Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $721.9 million in 2021, then dropped by 22.08% to $562.5 million in 2022, then tumbled by 70.61% to $165.3 million in 2023, then crashed by 38.52% to $101.6 million in 2024, then dropped by 12.78% to $88.6 million in 2025.
  • Its last three reported values are $88.6 million in Q3 2025, $97.6 million for Q2 2025, and $86.2 million during Q1 2025.